Array BioPharma Inc. Earnings Conference Call (Q3 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 6 Calls Today's Calls

Call Details Array BioPharma Inc. Earnings Conference Call (Q3 2008) Tue, May 6, 2008, 9:00 am Eastern Listen to the archived event audio About Array BioPharma Inc. (NasdaqGM:ARRY) Array BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted small molecule drugs to treat cancer and inflammatory diseases. Its products in development include ARRY-886, an MEK inhibitor, which is in multiple Phase II clinical trials; ARRY-543, an orally active dual inhibitor of EGFR and ErbB-2, which is in a Phase Ia clinical trial; ARRY-520, a kinesin spindle protein inhibitor, which is in Phase I clinical trials; ARRY-704, an MEK inhibitor, which is in Phase I clinical trial; and ARRY-162, an orally active MEK inhibitor, which is in Phase Ib trial for inflammation. The company is also developing ARRY-380, an orally active ErbB-2 inhibitor; ARRY-614, an orally active P38/Tie2 inhibitor, for cancer and inflammation; and ARRY-797, an orally active p38 inhibitor, which is in Phase I clinical trial for cancer and inflammation. Further, Array BioPharma’s products in clinical development comprise ITMN-191, a NS3/4 protease inhibitor; and IC83, a CHK-1 inhibitor. It has collaborations with AstraZeneca PLC; Genentech, Inc.; Amgen, Inc.; InterMune, Inc.; Ono Pharmaceutical Co., Ltd.; VentiRx Pharmaceuticals, Inc.; and Eli Lilly and Company. The company was founded in 1998 and is headquartered in Boulder, Colorado. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings